{
  "docId": "019de074-71be-772a-8bed-f9d5eaece76b",
  "docSlug": "e4f10758c80bf7a23f09bd201ccd4281",
  "documentTitle": "Alkermes | Investor Presentation Deck | 32 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 32,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 25,
  "notes": "The slide uses a human body diagram to map clinical responses (CR, PR, uPR) across various cancer types.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-71be-772a-8bed-f9d5eaece76b/25",
  "deckHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b",
  "deckJsonHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b.json",
  "deckAnchorHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "image",
      "text": "Body diagram mapping tumor responses",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d606d5f9-dd90-46dc-a0cd-1d871335404a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.42,
        "x": 0.08,
        "y": 0.62
      },
      "kind": "list",
      "text": "Pyrexia, chills and nausea were the most commonly reported AEs; Transient and asymptomatic neutropenia/neutrophil count decrease were the most commonly reported events of grade ≥3.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45f4f4e1-fd8f-4c54-a0cb-84ca502d7a96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Treatment-related adverse events (AEs) have been consistent with expectations based on nemvaleukin’s mechanism of action and were mostly transient and manageable.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e2695fa-432e-45d2-b763-57775c595ba9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Demonstrated durable responses in high unmet need populations; Monotherapy activity in prior anti-PD-(L)1 treated melanoma and renal cell carcinoma; Combination activity with pembrolizumab in a range of tumor types.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f9b9f79-c096-4163-9e24-626d7043e6af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Patients achieved SD (*acral), PR (*RCC), and PD (#RCC) on nemvaleukin monotherapy, rolled over to combination therapy and achieved PR. IV: Intravenous; NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer; RCC: Renal cell carcinoma; SCC: Squamous cell carcinoma CR: complete response; PR: partial response; uPR: unconfirmed PR",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79659708-c12f-4789-87bc-4f2053b2d707",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "ARTISTRY-1 (IV Nemvaleukin): Durable Responses Observed",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0eaaf944-a6a9-4d46-9621-319398653930",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}